Anticancer composition based on natural active ingredients and medicine thereof

Abstract

The invention relates to an anti-cancer composition based on natural active ingredients and a medicine thereof, and belongs to the technical field of medicine compositions. The anticancer composition based on the natural active ingredients is prepared from the following components in percentage by mass: 1 to 10 percent of ginsenoside Rg3, 5 to 20 percent of dihydroquercetin, 20 to 40 percent of lucid ganoderma extract, 15 to 30 percent of astragalus extract and 15 to 30 percent of coix seed extract. In the anti-cancer composition based on the natural active ingredients, ginsenoside Rg3 has the effect of inhibiting tumor angiogenesis; the dihydroquercetin has remarkable antioxidant and anti-inflammatory activity; ganoderma lucidum polysaccharide can enhance the immune function of the body. Astragaloside has an immunoregulation effect; coix seed ester has the anti-tumor metastasis activity, the anti-cancer effect is remarkably enhanced through the synergistic effect of multiple components, toxic and side effects are low, the composition is suitable for long-term taking, and the product quality is stable.

Description

Technical Field

[0001] The present invention belongs to the technical field of pharmaceutical compositions, and particularly relates to an anti-cancer composition based on natural active ingredients and a drug thereof. Background Art

[0002] Cancer has become a major disease seriously threatening human health. In the prior art, cancer treatment mainly relies on surgery, radiotherapy, and chemotherapy. However, the anti-cancer drugs used in these methods have problems such as poor selectivity, large toxic and side effects, and easy generation of drug resistance.

[0003] Due to the characteristics of multi-targets and low toxicity of natural drugs, they have become an important direction for the research and development of anti-cancer drugs in recent years. However, most of these natural drugs use single components or simple combinations, lacking research on scientific compatibility and synergistic enhancement of efficacy, and the anti-cancer effect is limited. For example, a pharmaceutical composition for preventing and treating lung cancer (publication number 119656217A) in a Chinese patent application contains icariin derived from Epimedium and daphnetin derived from Stellera chamaejasme. And traditional compound prescriptions lack modern scientific verification. There are problems such as large loss of active ingredients, low purity, and insufficient optimization of the extraction process in traditional extraction processes.

[0004] Therefore, it is of great significance to develop an anti-cancer composition of natural active ingredients with high efficiency, low toxicity, and multi-component synergistic anti-cancer effect. Summary of the Invention

[0005] The present invention aims to provide an anti-cancer composition based on natural active ingredients and a drug thereof. By scientifically combining ginsenoside Rg3, dihydroquercetin, Ganoderma lucidum extract, Astragalus membranaceus extract, and Coix lacryma-jobi extract, multi-target synergistic effects are achieved, the anti-cancer effect is improved, and the toxic and side effects are reduced at the same time.

[0006] The technical solutions adopted by the present invention to achieve the above object are as follows.

[0007] In the first aspect, the anti-cancer composition based on natural active ingredients of the present invention is composed of 1%-10% of ginsenoside Rg3, 5%-20% of dihydroquercetin, 20%-40% of Ganoderma lucidum extract, 15%-30% of Astragalus membranaceus extract, and 15%-30% of Coix lacryma-jobi extract by mass percentage.

[0008] Preferably, it is composed of 5% of ginsenoside Rg3, 10% of dihydroquercetin, 30% of Ganoderma lucidum extract, 25% of Astragalus membranaceus extract, and 30% of Coix lacryma-jobi extract by mass percentage.

[0009] Preferably, it is composed of 8% of ginsenoside Rg3, 15% of dihydroquercetin, 25% of Ganoderma lucidum extract, 22% of Astragalus membranaceus extract, and 30% of Coix lacryma-jobi extract by mass percentage.

[0010] Preferably, by mass percentage, it is composed of 10% of ginsenoside Rg3, 20% of dihydroquercetin, 20% of Ganoderma lucidum extract, 20% of Astragalus membranaceus extract, and 30% of Coix lacryma-jobi extract.

[0011] Preferably, the purity of the ginsenoside Rg3 ≥ 98%, and more preferably, the ginsenoside Rg3 is obtained by purification through macroporous resin combined with silica gel column chromatography.

[0012] Preferably, the purity of the dihydroquercetin ≥ 95%, and more preferably, the dihydroquercetin is extracted from larch bark and obtained by crystallization purification.

[0013] Preferably, the polysaccharide content of the Ganoderma lucidum extract ≥ 30%, and more preferably, the Ganoderma lucidum extract is prepared by hot water extraction combined with ethanol precipitation. Particularly preferably, the preparation method of the Ganoderma lucidum extract is: pulverize the Ganoderma lucidum fruiting body, extract with 10 times the amount of 80 °C hot water for 2 times, 2 hours each time, combine the extraction solutions, concentrate to a relative density of 1.10 - 1.15, add ethanol to a final concentration of 70%, stand for 24 hours, centrifuge, dry the precipitate, pulverize, and mix evenly to obtain the Ganoderma lucidum extract.

[0014] Preferably, the content of astragaloside IV in the Astragalus membranaceus extract ≥ 1%; more preferably, the Astragalus membranaceus extract is prepared by macroporous resin purification. Particularly preferably, the preparation method of the Astragalus membranaceus extract is: pulverize the Astragalus membranaceus medicinal material, extract with 8 times the amount of 60 °C hot water for 3 times, 1.5 hours each time, combine the extraction solutions, concentrate to a relative density of 1.05 - 1.10, pass through an AB-8 type macroporous resin column, first wash with 3 times the column volume of water, then elute with 5 times the column volume of 70% ethanol, collect the ethanol eluate, concentrate and dry, pulverize, and mix evenly to obtain the Astragalus membranaceus extract.

[0015] Preferably, the content of triolein in the Coix lacryma-jobi extract ≥ 5%, and more preferably, the Coix lacryma-jobi extract is prepared by supercritical CO2 extraction. Particularly preferably, the preparation method of the Coix lacryma-jobi extract is: pulverize the Coix lacryma-jobi, adopt supercritical CO2 extraction, extraction conditions: pressure 25 MPa, temperature 45 °C, time 2 hours, and store the extraction solution sealed at 2 - 10 °C to obtain the Coix lacryma-jobi extract.

[0016] The present invention also provides a drug containing the above anti-cancer composition based on natural active ingredients.

[0017] Preferably, the dosage form of the drug is capsule, tablet or oral liquid.

[0018] Compared with the prior art, the beneficial effects of the present invention are:

[0019] 1. In the anti-cancer composition based on natural active ingredients of the present invention, ginsenoside Rg3 has the effect of inhibiting tumor angiogenesis; dihydroquercetin has significant antioxidant and anti-inflammatory activities; ganoderma polysaccharide can enhance the immune function of the body; astragaloside has an immunomodulatory effect; coixenolide has anti-tumor metastasis activity, and the synergistic effect of multiple components significantly enhances the anti-cancer effect.

[0020] 2. The anti-cancer composition based on natural active ingredients of the present invention has low toxicity and side effects and is suitable for long-term use.

[0021] 3. The anti-cancer composition based on natural active ingredients of the present invention adopts advanced technologies such as supercritical CO2 extraction and macroporous resin purification, which improves the yield and purity of active ingredients and the product quality is stable. Detailed implementation mode

[0022] In order to further understand the present invention, the preferred implementation modes of the present invention are described below. However, it should be understood that these descriptions are only to further illustrate the features and advantages of the present invention rather than a limitation on the claims of the present invention.

[0023] The anti-cancer composition based on natural active ingredients of the present invention is composed of 1%-10% of ginsenoside Rg3, 5%-20% of dihydroquercetin, 20%-40% of ganoderma extract, 15%-30% of astragalus extract and 15%-30% of coix seed extract by mass percentage.

[0024] In the present invention, it is preferred that the purity of ginsenoside Rg3 ≥ 98%, and it is obtained by purification through macroporous resin combined with silica gel column chromatography. The mass percentage of ginsenoside Rg3 is 1%-10%, such as 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% in some implementation modes, but not limited thereto.

[0025] In the present invention, it is preferred that the purity of dihydroquercetin ≥ 95%, which is extracted from larch bark by dihydroquercetin and obtained by crystallization purification. The mass percentage of dihydroquercetin is 5%-20%, such as 5%, 10%, 15%, 20% in some implementation modes, but not limited thereto.

[0026] In the present invention, it is preferred that the polysaccharide content of the ganoderma extract ≥ 30%. The ganoderma extract is prepared by hot water extraction combined with ethanol precipitation. The specific method is: crush the ganoderma fruiting body, extract with 10 times the amount of 80°C hot water for 2 times, 2 hours each time, combine the extracts, concentrate to a relative density of 1.10 - 1.15, add ethanol to a final concentration of 70%, stand for 24 hours, centrifuge, dry the precipitate, crush and mix to obtain the ganoderma extract. The mass percentage of the ganoderma extract is 20%-40%, such as 20%, 25%, 30%, 35%, 40% in some implementation modes, but not limited thereto.

[0027] In the present invention, it is preferred that the content of astragaloside in the astragalus extract is ≥ 1%. The astragalus extract is prepared by purification with macroporous resin. The specific method is as follows: The astragalus medicinal materials are crushed, extracted with 8 times the amount of hot water at 60°C for 3 times, 1.5 hours each time. The extraction solutions are combined, concentrated to a relative density of 1.05 - 1.10, passed through an AB-8 type macroporous resin column, first eluted with 3 column volumes of water, and then eluted with 5 column volumes of 70% ethanol. The ethanol eluate is collected, concentrated and dried, crushed, and mixed evenly to obtain the astragalus extract. The mass percentage of the astragalus extract is 15% - 30%, such as 15%, 18%, 20%, 22%, 25%, 28%, 30% in some embodiments, but not limited thereto.

[0028] In the present invention, it is preferred that the content of triolein in the coix seed extract is ≥ 5%. The coix seed extract is prepared by supercritical CO2 extraction. The specific method is as follows: The coix seeds are crushed and extracted by supercritical CO2 extraction. The extraction conditions are: pressure 25 MPa, temperature 45°C, time 2 hours. The extract is stored sealed at 2 - 10°C to obtain the coix seed extract. The mass percentage of the coix seed extract is 15% - 30%, such as 15%, 18%, 20%, 22%, 25%, 28%, 30% in some embodiments, but not limited thereto.

[0029] In the present invention, the preparation method of the anti-cancer composition based on natural active ingredients is: taking each component according to the ratio and mixing evenly.

[0030] In the present invention, for the drug containing the anti-cancer composition based on natural active ingredients, the dosage form is not particularly limited, such as capsules, tablets or oral liquids. The preparation method of the drug is to add pharmaceutically acceptable excipients (such as microcrystalline cellulose, magnesium stearate, honey, water) according to the ratio of ginsenoside Rg3, dihydroquercetin, ganoderma extract, astragalus extract and coix seed extract according to the dosage form. The specific preparation can refer to the preparation methods of the corresponding dosage forms. Furthermore, the content of each active ingredient can be detected by HPLC for quality control.

[0031] In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention will be further described in detail below with reference to the embodiments.

[0032] In the following embodiments, various processes and methods not described in detail are conventional methods well known in the art. The materials, reagents, devices, instruments, equipment, etc. used in the following embodiments can be obtained from commercial channels without special instructions.

[0033] Example 1

[0034] An anti-cancer composition based on natural active ingredients, calculated by mass percentage, consists of 5% ginsenoside Rg3, 10% dihydroquercetin, 30% Ganoderma lucidum extract, 25% Astragalus membranaceus extract, and 30% Coix lacryma-jobi extract;

[0035] Among them, the purity of ginsenoside Rg3 ≥ 98%, and it is obtained by purification through macroporous resin combined with silica gel column chromatography;

[0036] The purity of dihydroquercetin ≥ 95%, and it is extracted from larch bark by dihydroquercetin and obtained by crystallization purification;

[0037] The polysaccharide content of the Ganoderma lucidum extract ≥ 30%. The preparation method of the Ganoderma lucidum extract is as follows: pulverize the Ganoderma lucidum fruiting body, extract it twice with 10 times the amount of 80°C hot water for 2 hours each time, combine the extraction solutions, concentrate to a relative density of 1.10 - 1.15, add ethanol to a final concentration of 70%, let it stand for 24 hours, centrifuge, dry the precipitate, pulverize, and mix evenly to obtain the Ganoderma lucidum extract;

[0038] The astragaloside content of the Astragalus membranaceus extract ≥ 1%. The preparation method of the Astragalus membranaceus extract is as follows: pulverize the Astragalus membranaceus medicinal material, extract it three times with 8 times the amount of 60°C hot water for 1.5 hours each time, combine the extraction solutions, concentrate to a relative density of 1.05 - 1.10, pass through an AB-8 type macroporous resin column, first elute with 3 times the column volume of water, then elute with 5 times the column volume of 70% ethanol, collect the ethanol eluate, concentrate and dry, pulverize, and mix evenly to obtain the Astragalus membranaceus extract;

[0039] The triolein content of the Coix lacryma-jobi extract ≥ 5%. The preparation method of the Coix lacryma-jobi extract is as follows: pulverize Coix lacryma-jobi, and extract it by supercritical CO2 extraction. The extraction conditions are: pressure 25 MPa, temperature 45°C, time 2 hours, and the extraction solution is stored sealed at 2 - 10°C to obtain the Coix lacryma-jobi extract.

[0040] A drug containing the above anti-cancer composition based on natural active ingredients, with the dosage form of capsules. The preparation method is as follows:

[0041] First, according to the ratio, stir and mix ginsenoside Rg3, dihydroquercetin, Ganoderma lucidum extract, Astragalus membranaceus extract, and Coix lacryma-jobi extract evenly to obtain an anti-cancer composition based on natural active ingredients;

[0042] Then, mix the anti-cancer composition based on natural active ingredients, 10 wt% microcrystalline cellulose, and 1 wt% magnesium stearate evenly to make capsules, with each capsule containing 500 mg of the anti-cancer composition based on natural active ingredients.

[0043] Example 2

[0044] An anticancer composition based on natural active ingredients, comprising, by mass percentage, 8% of ginsenoside Rg3, 15% of dihydroquercetin, 25% of ganoderma lucidum extract, 22% of astragalus extract and 30% of coix seed extract;

[0045] Among them, the purity of ginsenoside Rg3 is ≥98%, and it is obtained by macroporous resin combined with silica gel column chromatography;

[0046] The purity of dihydroquercetin is ≥95%, and dihydroquercetin is extracted from larch bark and purified by crystallization;

[0047] The polysaccharide content of the ganoderma lucidum extract is ≥30%. The preparation method of the ganoderma lucidum extract is as follows: crushing the ganoderma lucidum fruiting body, extracting it twice with 10 times the amount of 80°C hot water, each time for 2 hours, combining the extracts, concentrating to a relative density of 1.10-1.15, adding ethanol to a final concentration of 70%, standing for 24 hours, centrifuging, precipitating and drying, crushing, mixing, and obtaining the ganoderma lucidum extract;

[0048] The astragaloside content of the astragalus extract is ≥1%. The preparation method of the astragalus extract is as follows: crushing the astragalus medicinal material, extracting it with 8 times the amount of 60°C hot water for 3 times, each time for 1.5 hours, combining the extracts, concentrating to a relative density of 1.05-1.10, passing through an AB-8 macroporous resin column, first eluting with 3 times the column volume of water, then eluting with 5 times the column volume of 70% ethanol, collecting the ethanol eluate, concentrating and drying, crushing, mixing, and obtaining the astragalus extract;

[0049] The triolein content of coix seed extract is ≥5%. The preparation method of coix seed extract is as follows: crush the coix seed, extract it with supercritical CO2, and extract under the conditions of pressure 25MPa, temperature 45℃, time 2 hours, and store the extract at 2-10℃ in a sealed container to obtain the coix seed extract.

[0050] The drug containing the above anticancer composition based on natural active ingredients is in the form of tablets and is prepared by:

[0051] First, ginsenoside Rg3, dihydroquercetin, ganoderma lucidum extract, astragalus extract and coix seed extract are stirred and mixed uniformly according to the proportion to obtain an anticancer composition based on natural active ingredients;

[0052] Then, the anticancer composition based on natural active ingredients, 10 wt % of microcrystalline cellulose and 1 wt % of magnesium stearate are uniformly mixed to prepare tablets, each tablet containing 300 mg of the anticancer composition based on natural active ingredients.

[0053] Example 3

[0054] An anti-cancer composition based on natural active ingredients, calculated by mass percentage, consists of 8% ginsenoside Rg3, 15% dihydroquercetin, 25% Ganoderma lucidum extract, 22% Astragalus membranaceus extract, and 30% Coix lacryma-jobi extract;

[0055] Among them, the purity of ginsenoside Rg3 ≥ 98%, which is obtained by purification through macroporous resin combined with silica gel column chromatography;

[0056] The purity of dihydroquercetin ≥ 95%, which is extracted from larch bark by dihydroquercetin and obtained by crystallization purification;

[0057] The polysaccharide content of Ganoderma lucidum extract ≥ 30%. The preparation method of Ganoderma lucidum extract is as follows: pulverize the Ganoderma lucidum fruiting body, extract it twice with 10 times the amount of 80°C hot water for 2 hours each time, combine the extracts, concentrate to a relative density of 1.10 - 1.15, add ethanol to a final concentration of 70%, let it stand for 24 hours, centrifuge, dry the precipitate, pulverize, and mix evenly to obtain Ganoderma lucidum extract;

[0058] The content of astragaloside IV in Astragalus membranaceus extract ≥ 1%. The preparation method of Astragalus membranaceus extract is as follows: pulverize the Astragalus membranaceus medicinal material, extract it three times with 8 times the amount of 60°C hot water for 1.5 hours each time, combine the extracts, concentrate to a relative density of 1.05 - 1.10, pass through an AB-8 type macroporous resin column, first elute with 3 times the column volume of water, then elute with 5 times the column volume of 70% ethanol, collect the ethanol eluate, concentrate and dry, pulverize, and mix evenly to obtain Astragalus membranaceus extract;

[0059] The content of triolein in Coix lacryma-jobi extract ≥ 5%. The preparation method of Coix lacryma-jobi extract is as follows: pulverize Coix lacryma-jobi, extract it by supercritical CO2 extraction. The extraction conditions are: pressure 25 MPa, temperature 45°C, time 2 hours, and the extract is stored sealed at 2 - 10°C to obtain Coix lacryma-jobi extract.

[0060] A drug containing the above anti-cancer composition based on natural active ingredients, with the dosage form of oral liquid. The preparation method is as follows:

[0061] First, according to the ratio, stir and mix ginsenoside Rg3, dihydroquercetin, Ganoderma lucidum extract, Astragalus membranaceus extract, and Coix lacryma-jobi extract evenly to obtain an anti-cancer composition based on natural active ingredients;

[0062] Then, add water, honey (20 wt%), and excipient (ethylparaben, 0.1 wt%) to the anti-cancer composition based on natural active ingredients to make an oral liquid, and each 10 mL contains 1 g of the anti-cancer composition based on natural active ingredients.

[0063] Detect the performance of the anti-cancer composition based on natural active ingredients prepared in Examples 1 - 3.

[0064] The detection method is as follows: 615 inbred mice are divided into 5 groups, with 13 - 15 mice in each group. The experimental grouping is as follows: product prevention group (administer the anti-cancer composition based on natural active ingredients 7 days before the experiment); product treatment group (anti-cancer composition based on natural active ingredients); positive control group (PDD); combined treatment group (anti-cancer composition based on natural active ingredients + PDD); negative control group (normal saline). The dosage of the anti-cancer composition based on natural active ingredients is: 3 mg / kg, administered by gavage once a day for 24 consecutive days; the dosage of PDD is: 1 mg / kg, perfused intraperitoneally every other day. On the 25th day after tumor inoculation, the mice are decapitated to collect blood; the primary tumor and the lymph nodes (including metastatic tumors) at the right popliteal fossa and groin are taken, the tumor weight is weighed, and the tissues are fixed, sectioned, and stained with HE routinely. Flow cytometry is used to detect CD4 and CD8 in the serum. And SPSS8.0 software is applied. For count data, the mean ± s is used, and the t-test is adopted. P < 0.05 is regarded as having significant differences. The detection results of the anti-cancer composition based on natural active ingredients in Example 1 are shown in Tables 1 - 3.

[0065] Table 1 Tumor inhibition rate and lymph node metastasis inhibition rate of each group

[0066]

[0067]

[0068] It can be seen from Table 1 that the lymph node metastasis inhibition rate is: combined drug group > positive control group > product prevention group > product treatment group > negative control group. Compared with the negative control group, *P < 0.05.

[0069] Table 2 Comparison of tumor destruction degree in primary tumor and metastatic tumor tissues under light microscopy

[0070]

[0071] Table 3 CD4 / CD8 analysis of each experimental group

[0072] Grouping CD4 / CD8 (mean ± SD) P (compared with the negative control group) Product prevention group 1.8637±0.2129 0.001 Product treatment group 1.7731±0.1622 0.055 Combined drug group 1.7872±0.1381 0.027 Positive control group 1.6964±0.1440 0.391 Negative control group 1.6500±0.1584 —

[0073] The above experiments show that the anti-cancer composition based on natural active ingredients of the present invention has obvious anti-tumor effects, can enhance the anti-cancer effect of the chemotherapy drug PDD, inhibit lymphatic metastasis, and improve the immune function of tumor-bearing mice.

[0074] Obviously, the above embodiments are merely examples given for clear illustration and are not limitations on the embodiments. For those of ordinary skill in the art, other different forms of changes or variations can be made based on the above description. It is not necessary and impossible to enumerate all embodiments here. And the obvious changes or variations derived therefrom are still within the protection scope of the present invention.

Claims

1. An anti-cancer composition based on natural active ingredients, characterized in that, It is composed of 1% - 10% of ginsenoside Rg3, 5% - 20% of dihydroquercetin, 20% - 40% of Ganoderma lucidum extract, 15% - 30% of Astragalus membranaceus extract and 15% - 30% of Coix lacryma-jobi extract by mass percentage.

2. The anti-cancer composition based on natural active ingredients according to claim 1, characterized in that, It is composed of 5% of ginsenoside Rg3, 10% of dihydroquercetin, 30% of Ganoderma lucidum extract, 25% of Astragalus membranaceus extract and 30% of Coix lacryma-jobi extract by mass percentage; Or, it is composed of 8% of ginsenoside Rg3, 15% of dihydroquercetin, 25% of Ganoderma lucidum extract, 22% of Astragalus membranaceus extract and 30% of Coix lacryma-jobi extract; Or, it is composed of 10% of ginsenoside Rg3, 20% of dihydroquercetin, 20% of Ganoderma lucidum extract, 20% of Astragalus membranaceus extract and 30% of Coix lacryma-jobi extract.

3. The anti-cancer composition based on natural active ingredients according to claim 1, wherein The purity of the ginsenoside Rg3 ≥ 98%; The purity of the dihydroquercetin ≥ 95%; The polysaccharide content of the Ganoderma lucidum extract ≥ 30 wt%; The content of astragaloside IV in the Astragalus membranaceus extract ≥ 1 wt%; The content of triolein in the Coix lacryma-jobi extract ≥ 5 wt%.

4. The anti-cancer composition based on natural active ingredients according to claim 3, characterized in that, The ginsenoside Rg3 is obtained by purification through macroporous resin combined with silica gel column chromatography.

5. The anti-cancer composition based on natural active ingredients according to claim 3, characterized in that, The dihydroquercetin is extracted from larch bark and obtained by crystallization purification.

6. The anti-cancer composition based on natural active ingredients according to claim 3, characterized in that, The preparation method of the Ganoderma lucidum extract is: pulverize the Ganoderma lucidum fruiting body, extract with 10 times the amount of 80°C hot water twice, each time for 2 hours, combine the extracts, concentrate to a relative density of 1.10 - 1.15, add ethanol to a final concentration of 70%, stand for 24 hours, centrifuge, dry the precipitate, pulverize, and mix evenly to obtain the Ganoderma lucidum extract.

7. The anti-cancer composition based on natural active ingredients according to claim 3, characterized in that, The preparation method of the Astragalus membranaceus extract is: pulverize the Astragalus membranaceus medicinal material, extract with 8 times the amount of 60°C hot water three times, each time for 1.5 hours, combine the extracts, concentrate to a relative density of 1.05 - 1.10, pass through an AB-8 macroporous resin column, first elute with 3 times the column volume of water, then elute with 5 times the column volume of 70% ethanol, collect the ethanol eluate, concentrate and dry, pulverize, and mix evenly to obtain the Astragalus membranaceus extract.

8. The anti-cancer composition based on natural active ingredients according to claim 3, characterized in that, The preparation method of the Coix lacryma-jobi extract is: pulverize Coix lacryma-jobi, adopt supercritical CO2 extraction, extraction conditions: pressure 25 MPa, temperature 45°C, time 2 hours, and store the extract sealed at 2 - 10°C to obtain the Coix lacryma-jobi extract.

9. A drug containing the anti-cancer composition based on natural active ingredients according to any one of claims 1 - 8.

10. The drug according to claim 9, characterized in that, The dosage form is capsule, tablet or oral liquid.

Images